LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split became effective at the opening of trading on July 15, 2026, following the publication of the corporate action on the FINRA Daily List. The forward split, combined with a mandatory share exchange and new CUSIP number, marks a significant corporate milestone for the development-stage digital health company.
The forward stock split increases the number of outstanding shares, potentially making the stock more accessible to investors. In connection with the split, the company's common stock now trades under the temporary symbol LMEDD, which is expected to revert to LMED after approximately 20 business days. The new CUSIP number is 21116R404, while the prior CUSIP 21116R305 has been suspended.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms."
Shareholders holding shares through brokerage accounts or in electronic form do not need to take any action, as the corporate action is processed automatically. Those with physical stock certificates are not required to surrender them immediately, but when exchanged, they will be processed under the new CUSIP.
The forward stock split and share exchange are part of LataMed AI's broader strategy to restructure its capital stock and position itself for future growth. The company focuses on developing AI-enabled healthcare solutions for emerging markets, with platforms like CardioAI, PulmoAI, and NeuroAI targeting cardiovascular, pulmonary, and neurological diagnostics.
For more information, visit https://latamed.ai or review the company's filings with the SEC at www.sec.gov.
This corporate action underscores LataMed AI's commitment to its long-term strategy, though the company remains in the development stage and faces risks typical of emerging technology firms. Investors are advised to review all risk factors in the company's SEC filings.
